Alpha-1 and Your Lungs
Whether you've already been diagnosed with Alpha-1 antitrypsin deficiency (AATD) or you're just beginning to explore it, this is your place to start. Alpha-1 is a genetic condition—meaning you're born with it. Alpha-1 can affect your lungs, and many people don't know they have it. Testing is the only way to know whether Alpha-1 may be affecting you or your family.
Get the full picture of your risk by uncovering a hidden cause of lung disease.
Even if you have another lung condition, you could have Alpha-1. In fact, 90% of people living with Alpha-1 don't know it. Genetic testing is the only way to know for sure.
Already diagnosed? Understand alpha-1 protein levels.
Your SERPINA1 gene—sometimes described using combinations such as MM, MZ, SZ, or ZZ—is one part of your Alpha-1 profile. To understand your risk, it's important to get the full picture of your Alpha-1 diagnosis.
Living with Alpha-1
An Alpha-1 antitrypsin diagnosis is a starting point, not a setback. Discover ways to help support your lung health and take control of your Alpha-1.
Take steps to help protect your lung health
Regular monitoring, knowing your alpha-1 protein levels, avoiding smoking and lung irritants, and maintaining regular care are important steps for people affected by Alpha-1. Find tools and resources to help you stay informed and prepared.
*Each patient story reflects the real-life experiences of individuals diagnosed with Alpha-1. Individual experiences may vary. Patients were compensated for their time by Sanofi.
Frequently asked questions
What is Alpha-1 antitrypsin deficiency?
Alpha-1 is an inherited genetic condition that can cause low or below normal levels of alpha-1 protein.
What is alpha-1 protein?
Alpha-1 antitrypsin is a protein made primarily in the liver that helps protect lung tissue from damage.
What does Alpha-1 antitrypsin deficiency cause?
Alpha-1 can increase the risk of lung diseases such as emphysema and COPD, as well as liver disease.
How common is Alpha-1 antitrypsin deficiency?
Alpha-1 is considered rare and is estimated to affect 70,000-100,000 individuals in the US, with many remaining undiagnosed. It is identified through testing.